Key Drivers
- High margins
- Strong cash conversion
- Premium valuation
AIAI Summary
Krystal's evolution into a high‑margin, cash‑generative rare‑disease commercial company (with VYJUVEK funding a multicandidate pipeline) shifts the investment case from a binary trial bet to a commercial‑plus‑pipeline growth equity—investors should therefore monitor VYJUVEK volume/adoption, timing of ex‑US CMC and reimbursement approvals, and near‑term readouts (eg KB407) as the decisive catalysts that will validate sustained cash flow and justify the premium or, if they falter, rapidly re‑rate the stock.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •High margins
- •Strong cash conversion
- •Premium valuation
KRYS delivers exceptional profitability and cash generation with minimal leverage, but modest asset turnover and a premium valuation leave little margin for error.
Price Behavior
Key Price Behavior Insights:
- •Lower highs
- •Support bounces
- •Neutral momentum
Mild short‑term downtrend over the last month from $261.80 to $251.68 (~3.9%) with lower highs around $276.36, neutral momentum (RSI ~55), key support near $247.26 and resistance in the mid‑to‑high $270s.
Mild decline of ~3.9% from $261.80 to $251.68 over the last month with failed follow‑through after the $276.36 peak
Sentiment & News
Key News Insights:
- •Post-earnings drop
- •Unclear drivers
- •Near-term focus
Krystal Biotech shares fell 11.5% in the month after its recent earnings report, leaving investors focused on near-term catalysts amid no further public news.
The unexplained decline heightens short-term volatility and likely keeps the stock pressured until clearer guidance, trial updates, or financial details are released
Similar Companies in Healthcare
Other companies in the same sector with AI ratings